Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
PCVX
PCVX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
PCVX News
Vaxcyte Initiates Phase 3 Trial for VAX-31 Vaccine
3d ago
NASDAQ.COM
Vaxcyte Prices Public Offering at $550 Million
Jan 30 2026
Newsfilter
Vaxcyte Initiates Phase 3 Trials for VAX-31, Market Cap Around $7 Billion
Jan 23 2026
Benzinga
Vaxcyte Advances VAX-31 Vaccine with 95% Coverage for Adults
Jan 23 2026
NASDAQ.COM
Stocks to Consider Buying in 2026: Insights from Our Roundtable Experts, Including DoorDash and LVMH
Jan 16 2026
Barron's
Vaxcyte CTO Sells 9,743 Shares Worth Approximately $454,891 Amidst Stock Decline
Jan 03 2026
NASDAQ.COM
Vaxcyte's CTO Sells 9,743 Shares Valued at Approximately $454,891
Jan 03 2026
Fool
This Pharmaceutical Stock Struggled Last Year, But One Analyst Believes It Could Surge 250%.
Dec 22 2025
Barron's
Mizuho's Lesser-Known Stock Choice for 2026: A Wall Street Favorite That Could See Its Value Triple
Dec 20 2025
CNBC
Eight Stock Selections to Capitalize on a Robust Sector of the Market
Dec 11 2025
MarketWatch
Vaxcyte Administers Initial Doses to Patients in Phase 3 Trial of VAX-31 for Invasive Pneumococcal Disease and Pneumonia
Dec 08 2025
Yahoo Finance
Vaxcyte Initiates Phase 3 Trial for VAX-31 Vaccine, Aiming 95% Coverage
Dec 08 2025
Globenewswire
The Biotech Sector Is Stronger Than Investors Realize: Key Stocks to Monitor.
Dec 04 2025
Barron's
Vaccine Shares Drop After FDA Official Connects COVID Vaccines to Heart Issues in Young Men
Dec 01 2025
MarketWatch
CleanSpark, Cipher Mining, Bitdeer Technologies, and Other Major Stocks Decline in Monday's Pre-Market Trading
Dec 01 2025
Benzinga
S&P 500 Futures Decline in Pre-Market Trading; Vaxcyte and Cipher Mining Underperform
Dec 01 2025
Barron's
Show More News
